Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Constellation Energy Corporation (CEG) vs Novavax Inc (NVAX) Price & Performance

Constellation Energy CorporationTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Constellation Energy Corporation vs Novavax Inc — how do they compare? Constellation Energy Corporation trades at $257.84 (market cap $91.57B), while Novavax Inc trades at $8.42 (market cap $1.38B). The key difference: Constellation Energy Corporation is far larger — about 66.4× Novavax Inc's market cap, and Constellation Energy Corporation pays a 0.67% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

CEGNVAX
Market Cap
$91.57B$1.38B
Sector
EnergyHealth
52-Week High
$403.95$11.19
52-Week Low
$236.50$6.22
Enterprise Value
$113.24B$889.29M
Dividend Yield
0.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Constellation Energy Corporation

Constellation Energy (CEG) trades at $257.57, up 2.46% today, showing strong momentum despite a bearish technical signal. The stock benefits from robust fundamentals with 2025 revenue of $25.53B and net income of $2.32B, supported by a 70% analyst buy rating and consensus price target of $343.50. Recent news highlights CEG's strategic positioning to capitalize on rising AI-driven electricity demand and nuclear power resurgence.

The outlook remains positive with CEG positioned as a key beneficiary of growing electricity demand from AI and data centers. Investment opportunities include strong earnings growth projections and favorable valuation metrics. Risks include execution challenges in capacity expansion and potential regulatory changes affecting utility operations.

Novavax Inc

Novavax (NVAX) trades at $8.91, down 4.5% today, with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong revenue of $1.12B in 2025 but negative equity of -$623.84M. Analyst consensus remains bullish with a $14.00 price target, though cash flow trends show ongoing operational losses. Recent news highlights shareholder dissent and market underperformance compared to peers.

The outlook is cautious; while valuation ratios like P/E of 3.14 appear attractive, persistent negative cash flow and high liabilities pose significant risks. Upside depends on sustainable profitability and execution amid competitive vaccine markets. Investors should weigh analyst optimism against fundamental weaknesses and volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Constellation Energy Corporation

Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.

Read more on CEG

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX